Updated Jul 16, 2026
Chu Yu-Waye is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $137K.
Yu-Waye Chu is the Chief Medical Officer at CytomX Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. He has been involved in the company's efforts to create novel antibody therapeutics utilizing probody technology.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-19 | CTMX | CytomX Therapeutics, Inc. | S — Open-market sale | 21.3K | $6.42 | $137K |
| 2026-02-04 | CTMX | CytomX Therapeutics, Inc. | A — Grant or award | 75.0K | $0.00 |
Yu-Waye Chu is the Chief Medical Officer at CytomX Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. He has been involved in the company's efforts to create novel antibody therapeutics utilizing probody technology.…
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($137K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Chu Yu-Waye profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.